Treatment of Alzheimer's disease.
A growing consensus indicates that Alzheimer's disease (AD) results from an increase in the production or accumulation of beta-amyloid protein (A beta) leading to nerve cell death. Mechanisms by which A beta accumulation leads to neuronal death include oxidative damage and inflammation. This article discusses the management of AD patients with antioxidants, cholinesterase inhibitors, and psychotropic agents. Studies show that these agents can slow the progression of the disease, improve cognition, and reduce behavioral disturbances. A therapeutic alliance between physician and caregiver is an essential element in successfully managing the AD patient. The 3Rs--repeat, reassure, and redirect--can help caregivers reduce behavioral disturbances in patients with AD and limit the need for pharmacologic management.
Cummings
J L
JL
UCLA Alzheimer's Disease Center, UCLA School of Medicine, Los Angeles, California, USA.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000975:Antioxidants / Q000627:therapeutic use*; D017028:Caregivers / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D014810:Vitamin E / Q000009:adverse effects / Q000627:therapeutic use*
D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D011619:Psychotropic Drugs; D014810:Vitamin E